METHOD FOR PRODUCING BRAIN ORGANOIDS
A method for producing a brain organoid is provided, including a step of culturing a neuroectoderm marker-positive cell aggregate in a medium containing an extracellular matrix with a concentration of more than 10% by volume.
1 . A method for producing a brain organoid, the method comprising:
(i) culturing a neuroectoderm marker-positive cell aggregate in a medium comprising an extracellular matrix with a concentration of more than 10% by volume.
2 . The method according to claim 1 , wherein a concentration of the extracellular matrix in the medium is 20% by volume to 50% by volume.
3 . The method according to claim 1 ,
wherein the medium further comprises a Wnt signal enhancer.
4 . The method according to claim 1 ,
wherein the medium further comprises a transforming growth factor β family signal transduction pathway inhibitor.
5 . The method according to claim 1 ,
wherein the (i) culturing of the neuroectoderm marker-positive cell aggregate is performed in a dispersed state without inserting the cell aggregate into the extracellular matrix.
6 . The method according to claim 1 , further comprising:
(ii) culturing in a medium substantially not containing an extracellular matric after the (i) culturing.
7 . The method according to claim 6 ,
wherein the (ii) culturing is performed by suspension culture.
8 . The method according to claim 6 ,
wherein the (ii) culturing is performed under high oxygen partial pressure conditions.
9 . The method according to claim 6 ,
wherein the (ii) culturing is performed while stirring.
10 . The method according to claim 1 ,
wherein the neuroectoderm marker-positive cell aggregate is derived from a human.
11 . A brain organoid produced by the method according to claim 1 .
12 . The brain organoid according to claim 11 , comprising:
a telencephalic marker-positive cell.
13 . The brain organoid according to claim 12 , further comprising:
a telencephalic partial tissue marker-positive cell.
14 . The brain organoid according to claim 13 ,
wherein the telencephalic partial tissue marker-positive cell is at least one selected from the group consisting of a cerebral cortex, a basal ganglia, a hippocampus, and a choroid plexus.
15 . A kit, comprising: the brain organoid according to claim 11 .
16 . A method for evaluating drug efficacy of a test substance, the method comprising:
contacting the test substance with the brain organoid according to claim 11 ; and
testing an effect of the test substance on the brain organoid.
17 . A therapeutic agent comprising:
the brain organoid according to claim 11 .
18 . A pharmaceutical composition comprising:
the brain organoid according to claim 11 as an effective component.
19 . A method for treating a disease based on a disorder of a nervous system cell or a nervous tissue, the method comprising:
transplanting an effective dose of the brain organoid according to claim 11 into a brain of a patient in need of treatment.